At any rate, similar analyses can be developed for non-FDG tracers, e.g. with SSTR ligands in neuroendocrine tumors and PSMA ligands in prostate cancer, Na18F in breast and prostate cancer patients (184–187). The gene discussed is FOLH1; the disease is prostate cancer.